title: Selective estrogen receptor modulators (SERMs): a review of clinical data.
abstract: SERMs represent a diverse group of molecules with varying levels of estrogenic agonist and antagonist activity in target tissues. SERMs have a long regulatory approval history and have been studied for a variety of therapeutic indications. The clinical effects of SERMs have been evaluated in a large number of phase 3 clinical trials. Many of the available SERMs have proved to be effective as chemo-preventive agents and treatments for breast cancer and a number are useful for the prevention and treatment of osteoporosis. The endometrial effect of SERMs has been a key differentiator in clinical practice and a major hurdle for regulatory approval. The effect of SERMs in the vagina also represents a major distinction among different SERMs. This review summarized key clinical finding of SERMs in different target tissues.
authors.affiliation: TherapeuticsMD, Boca Raton, FL, USA.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Mirkin
authors.affiliation: Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA. Electronic address: jhpickar@me.com.
authors.forename: James H
authors.initials: JH
authors.lastname: Pickar
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016387:Women's Health
chemical_list: D020845:Selective Estrogen Receptor Modulators
keywords: Breast cancer; Endometrial cancer; Menopause; Osteoporosis; SERM